1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Iconovo AB (publ)

Iconovo AB (publ)

ICO.ST
Iconovo AB (publ)SE flagStockholm Stock Exchange
1.11
SEK
+0.03
- -
57.46MMarket Cap
Iconovo AB (publ)
ICO.ST
(Stockholm Stock Exchange)

Recent

price

1.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.27
3.38
1.66
1.57
2.07
1.68
1.75
0.61
0.18
0.03
0.06
Revenue per Share
0.39
0.24
-0.6
-1.52
-1.99
-2.85
-4.93
-3.97
-2.57
-1.14
-1.6
Basic EPS, GAAP
0.7
-1.41
-0.86
-2.68
-3.32
-4.02
-8.25
-5.32
-2.9
-1.21
-1.58
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.16
-0.78
-3.27
-5.4
-6
-10.57
-12.89
-11.83
-6.03
-7.64
Book Value per Share
0.33
4.46
7.67
12.37
8.15
10.31
2.14
2.48
1.77
0.2
1.19
Tangible Book Value per Share
6
6
7
7
9
9
10
12
16
38
27
Basic Weighted Avg Shares
14
20
12
12
18
15
17
7
3
1
2
Sales/Revenue/Turnover
25.08
17.48
-34.44
-99.92
-92.69
-172.06
-282.53
-646.72
-1,400.06
-3,902.77
-2,733.42
Operating Margin (%)
1
1
2
3
4
5
10
18
11
10
11
Depreciation Expense
2
1
-4
-11
-17
-26
-48
-46
-41
-43
-44
Net Income, GAAP
14.46
5.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
17.12
7.24
-36.06
-97.04
-96.3
-169.77
-281.39
-648.37
-1,402.23
-3,925.5
-2,754.11
Profit Margin (%)
5
24
51
91
66
90
9
17
18
- -
23
Working Capital
2
- -
- -
- -
- -
- -
8
5
4
1
3
LT Debt
9
33
64
109
93
137
89
114
129
118
139
Total Equity
- -
14.86
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
103.64
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
3
3
4
LT Borrowings
- -
- -
- -
LT Finance Leases
4
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
53
Market Capitalization
68
49
52

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
30
16
37
Cash, Cash Equivalents & STI
30
16
37
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
12
12
14
Payables & Accruals
- -
- -
- -
ST Debt
3
3
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.04%
-8.74%
Free Cash Flow
- -
19.72%
-1.04%
Net Income, GAAP
- -
25.43%
5.41%
Sales/Revenue/Turnover
- -
-36.37%
-62.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
- -
- -
1
3
2025
- -
- -
1
- -
1
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.62
-0.6
-0.7
-0.59
-2.57
2025
-0.53
-0.2
-0.24
- -
-1.14
2026
-0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Lifecare AS (LIFE.OL)
Quotient Limited (QTNT)
ALR Technologies Inc. (ALRTF)
ResMed Inc. (0KW4.L)
SI-BONE, Inc. (SIBN)
ReShape Lifesciences Inc. (RSLS)
Business
Iconovo AB (publ) specializes in the development and licensing of complete inhaled medicinal products in Sweden and for global markets. The company provides a unique combination of proprietary dry powder inhaler devices and in-house formulation expertise, enabling pharmaceutical partners to bring both generic and novel therapeutics to market. Their portfolio of patented inhaler platforms includes ICOres, a flexible multi-dose device designed to accommodate various medications, ICOcap, a capsule-based dry powder inhaler, ICOone, a single-dose disposable inhaler, which also has a nasal variant, ICOone Nasal, and ICOpre, a pre-metered multi-dose system. Iconovo collaborates with international pharmaceutical companies, offering comprehensive development services, from initial concept through to manufacturing of clinical trial materials and technical documentation. Its revenue model is based on development fees, technology access fees for exclusive rights to drug-inhaler combinations, and royalties on product sales. Current key projects involve a partnership with Amneal Pharmaceuticals for a generic version of Symbicort, utilizing the ICOres platform, which has shown positive clinical pilot study results, and ongoing formulation development with Kiox Pharma for an inhaled treatment for interstitial lung disease using ICOcap. The company has also initiated the strategic development of intranasally inhaled semaglutide for obesity and metabolic diseases in its ICOone Nasal device. Iconovo aims to reduce development time and risk for its partners, positioning itself as a leader in innovative inhalation therapy. Founded in 2013, Iconovo AB (publ) is headquartered in Lund, Sweden.